Dermatomyositis (DM) is a systemic inflammatory disease affecting skeletal muscles and other organs. Spontaneous pneumomediastinum (PnM) has been previously reported as a rare complication of DM and it is known to occur more frequently in patients with interstitial lung disease (ILD). Here we report on a case of a 52-year-old woman with DM who developed spontaneous PnM, which was treated successfully with high-dose steroid pulse therapy and cyclosporine A (CsA). This case suggests that CsA can be an effective therapeutic agent in DM refractory to glucocorticoid therapy, with ILD or pulmonary fibrosis accompanied by DM. CsA should be considered as an initial immunosuppressive agent for patients with PnM in DM.
Introduction
Dermatomyositis (DM) is a systemic inflammatory disease affecting skeletal muscles and other organs. In 10∼22% of cases, pulmonary signs are related to aspiration pneumonia or respiratory muscle weakness (1) . Clinically apparent respiratory diseases developed in up to 50% of patients with DM and interstitial lung disease (ILD) is present in 10∼43% of cases and are associated with a poor outcome (1, 2) .
Spontaneous pneumomediastinum (PnM) has been previously reported as a rare complication of DM and it is known to be more frequent in patients with ILD (3) . Spontaneous PnM in DM patient is life-threatening, and aggressive high-dose steroid pulse therapy with immunosuppressive agents is recommended. Here we report a case of a 52-year-old woman with DM who developed spontaneous PnM which was successfully treated with high-dose steroid pulse therapy and cyclosporine A (CsA).
Case Report
A 52-year-old woman visited our hospital with complaints of general weakness, swallowing difficulty, arthralgia, and skin erythema for 5 months. There were periungual erythema ( Figure 1A ) and typical Gottron's sign on her knuckles of the proximal interphalangeal joints ( Figure 1B PnM was diagnosed by X-ray finding of subcutaneous emphysema with free air along cardiac border (Figure 2A and 2C ).
High-dose steroid pulse therapy (1 g of IV methylprednisolone) was started with oral CsA (100 mg twice a day). High dose oxygen supply and absolute bed rest were ordered. After treatments described above, subcutaneous emphysema and PnM gradually disappeared ( Figure 2B and 2D) , and muscle weakness was also improved. Prednisolone was tapered and the patient discharged for the outpatient department. (Table 1) .
Discussion
Recently, CsA has been reported to be an effective treatment for DM complicated with PnM. After CsA was actively applied to DM patients with spontaneous PnM in early phase, the clinical courses of them have been significantly improved (Table 1) .
Summary
We herein reported a rare case of a patient with DM, who developed PnM and who was treated with CsA. This case suggests that CsA can be an effective therapeutic agent in DM with ILD or pulmonary fibrosis refractory to glucocorticoid therapy. CsA should be considered as an initial immunosuppressive agent for patients with PnM in DM.
